Comparison
6q Terminal Deletion Syndrome C4304514 vs 17 20 Lyase Deficiency Isolated C3277849
Clinical comparison between 6Q Terminal Deletion Syndrome and 17 20 Lyase Deficiency Isolated for differential diagnosis and treatment planning.
6q Terminal Deletion Syndrome C4304514
A chromosomal disorder involving deletion of genetic material at the end of chromosome 6, leading to developmental delays and variable physical features.
17 20 Lyase Deficiency Isolated C3277849
A rare enzymatic disorder affecting sex hormone production. Impairs development of sexual characteristics in both males and females. Treatment involves hormone supplementation.
6 comparison axes
Onset
6q Terminal Deletion Syndrome C4304514
0-0
17 20 Lyase Deficiency Isolated C3277849
0-18
Onset patterns differ
Severity
6q Terminal Deletion Syndrome C4304514
severe
17 20 Lyase Deficiency Isolated C3277849
severe
Different severity levels
Chronic
6q Terminal Deletion Syndrome C4304514
Chronic
17 20 Lyase Deficiency Isolated C3277849
Chronic
Differing course
Communicable
6q Terminal Deletion Syndrome C4304514
No
17 20 Lyase Deficiency Isolated C3277849
No
Different transmission
Body System
6q Terminal Deletion Syndrome C4304514
congenital
17 20 Lyase Deficiency Isolated C3277849
endocrine
Same/different system
Category
6q Terminal Deletion Syndrome C4304514
genetic
17 20 Lyase Deficiency Isolated C3277849
endocrine
Different category
Bottom line
6q-terminal-deletion-syndrome-C4304514 and 17-20-lyase-deficiency-isolated-C3277849 differ in etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 6q Terminal Deletion Syndrome C4304514 | 17 20 Lyase Deficiency Isolated C3277849 | Discriminating power |
|---|---|---|---|
| Development | Developmental delay is described and may be prominent. | Primary developmental delay is not established by the source. | High |
| Physical features | Variable congenital or dysmorphic features may occur. | Main reported effect is impaired sexual-characteristic development. | Moderate |
| Puberty and sex steroids | A specific sex-steroid defect is not established. | Sex-hormone production is impaired in both sexes. | High |
When to favor each condition
Choose 6q Terminal Deletion Syndrome C4304514 when
Congenital developmental concern
Onset is described at birth and the category is genetic.
Moderate
Variable physical anomalies
The source emphasizes variable physical features rather than an enzyme defect.
Moderate
Suspected chromosomal deletion
The named mechanism is terminal loss of chromosome 6 material.
High
Choose 17 20 Lyase Deficiency Isolated C3277849 when
Disordered sexual development
The source specifically describes impaired sexual characteristics.
High
Childhood or adolescent endocrine presentation
Reported onset spans birth through age 18.
Moderate
Need for hormone supplementation
Treatment is described as hormone supplementation, without a dose specified.
Moderate
How key tests differ
| Test | 6q Terminal Deletion Syndrome C4304514 | 17 20 Lyase Deficiency Isolated C3277849 | Interpretation |
|---|---|---|---|
| Chromosomal microarray or karyotype | May identify a terminal chromosome 6 deletion. | Not expected to define this enzyme disorder. | A chromosomal result supports the left concept but needs specialist review. |
| Sex-steroid and precursor evaluation | No characteristic pattern is established. | May show impaired sex-hormone production; exact cutoffs are not supplied. | Abnormal hormones are findings, not a complete diagnosis. |
| Targeted genetic or enzyme assessment | Directed at chromosomal material rather than steroid-enzyme function. | May be used to evaluate the suspected lyase defect. | Test choice should follow clinical genetics or endocrinology assessment. |
Prognosis comparison
6q Terminal Deletion Syndrome C4304514
- Outcome
- Chronic and potentially severe, with variable developmental impact.
- Factors
- Deletion extent, associated anomalies, and developmental support may influence course.
17 20 Lyase Deficiency Isolated C3277849
- Outcome
- Chronic endocrine condition; sexual development may be affected.
- Factors
- Hormone findings, sex-development effects, and response to clinician-directed treatment matter.
Time frame: Lifelong follow-up is generally appropriate; exact prognosis is not established.
Neither source provides mortality, prevalence, or definitive outcome data.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental impairment | Delays are a described feature and may be chronic. Not established as a core feature. Severity and support needs vary; no outcome rate is supplied. |
| Sexual development | A specific pattern is not established. Impaired sexual characteristics may affect puberty and fertility. Clinical effects require individualized endocrine interpretation. |
| Multisystem congenital issues | Variable physical features may accompany the deletion. The supplied description centers on endocrine sex-hormone effects. Additional anomalies should not be assumed without evaluation. |
Patient education highlights
- HighDifferent causes
One is a chromosomal deletion; the other is a rare steroid-enzyme disorder.
- HighSpecialist care
Genetics and endocrinology interpretation is needed before labeling either condition.
- MediumTreatment boundaries
Hormone supplementation is described for the enzyme disorder, but no dose is established here.